AbbVie Inc. Annual Report, Year Ended Dec 31, 2012

AbbVie Inc. (ABBV) filed its 2013 10-K report, detailing its first full year as an independent entity following its spin-off from Abbott Laboratories on January 1, 2013. The company is a research-based biopharmaceutical firm focused on developing and marketing advanced therapies for complex diseases. Its product portfolio is heavily reliant on HUMIRA, which accounted for approximately 50% of total sales in 2012 ($9.3 billion), and is expected to drive significant future growth. AbbVie's strategy centers on expanding HUMIRA's indications, advancing its robust pipeline of over 20 compounds in Phase II or III development across key therapeutic areas like immunology, oncology, and neuroscience, and increasing its presence in emerging markets. The report highlights AbbVie's strong financial performance despite the ongoing costs and complexities associated with operating as a standalone company. Key financial metrics include net sales of $18.38 billion and net earnings of $5.275 billion for the year ended December 31, 2012. The company has also secured a significant debt facility and has a clear dividend policy in place. Investors should note the upcoming patent expirations for key products, particularly HUMIRA's composition of matter patent in December 2016, as a potential future challenge, although the company's pipeline and ongoing R&D efforts aim to mitigate these risks.